Guido Cefarelli

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study

M. Rizzo, A. Sola, M. Chacón, 2022, World journal of clinical oncology.

Cisplatin, Docetaxel and Cetuximab (TPEx) as First-line Treatment for Patients With Recurrent or Metastatic Head and Neck Cancer: A Multicenter Real-World Study

M. Rizzo, A. Sola, M. Chacón, 2020 .